Skip to content

Effects of psilocybin on functional connectivity measured with fNIRS: Insights from a single-subject pilot study

Felix Scholkmann, Lisa Holper, Katrin H. Preller, Franz X. Vollenweider

Zurich Open Repository and Archive (University of Zurich) 2019 DOI: 10.5167/uzh-181782 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Single-subject pilot study Peer reviewed
Sample size 1
Population A 31-year-old man
Intervention Psilocybin
Dose 17 mg
Duration Measurements before intake and 30 and 60 minutes after intake
Topics Psilocybin
Keywords Subject documents Functional connectivity Functional near-infrared spectroscopy Cognitive psychology Artificial intelligence
Citations 6
Key points fNIRS detected psilocybin-induced changes in resting-state functional connectivity in bilateral frontal, bilateral occipital, and fronto-occipital regions.

Abstract

The serotonergic hallucinogen psilocybin has characteristic effects on human brain activity and subjective experience. Previous functional magnetic resonance imaging (fMRI) studies showed alternations of functional connectivity (FC) under the influence of psilocybin in humans. No study, as yet, investigated psilocybin-induced changes in brain hemodynamics and oxygenation with functional near-infrared spectroscopy (fNIRS) optical neuroimaging. Our aim was to perform the first fNIRS single-subject pilot study in order to investigate the ability of fNIRS to detect changes induced by psychedelic substances. To this end, psilocybin (17 mg) was administered orally to a 31-year old man while resting-state changes in cerebral tissue hemodynamic and oxygenation were measured with fNIRS bilaterally over the frontal and occipital cortex. Measurements were performed before the intake of the substance as well as during its effective period (30 min and 60 min after intake). We observed psilocybin-induced changes in the bilateral frontal FC, bilateral occipital FC as well as right and left frontooccipital FC. In addition, the pulse rate of the subject showed non-random variations during the experiment, possibly related to psilocybin administration. This study demonstrates that fNIRS is able to detect psilocybin-induced changes in resting-state FC. The results of this initial single-subject pilot study are promising and warrants repetition with a larger number of subjects and an improved/extended fNIRS setup. We anticipate that fNIRS neuroimaging will play an important role in future studies investigating the neuronal/physiological effects of psychedelic substances in humans.

Comparable studies

Other non-randomized and open-label trials on psilocybin, most cited first.

Study Year Design Participants
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Patients with moderate-to-severe, unipolar, treatment-resistant major depression 2016 Open-label feasibility trial n = 12
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Patients with severe, unipolar, treatment-resistant major depression 2017 Open-label trial n = 20
Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction Psychiatrically healthy nicotine-dependent smokers 2014 Open-label pilot study n = 15
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression Patients with treatment-resistant depression 2018 Clinical trial n = 20
Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder Subjects with obsessive-compulsive disorder (OCD) 2006 Controlled clinical trial

Citations in the library

Explore topics